[Ten-year experience with the use of ofloxacin in the treatment of wound infection].
The experience with ofloxacin used for 10 years from 1986 to 1995 in the complex therapy of 208 patients with wound infection complicated in 51 patients (24.5 per cent) by respiratory tract infection such as purulent tracheobronchitis or pleuropneumonia was generalized. In 28 patients (13.5 per cent) persistent bacteriuria not susceptible to the routine drugs was stated. The clinical and bacteriological efficacies of ofloxacin in the group of the patients with noncomplicated purulent wounds of the soft tissues amounted to 85-91 and 74-80 per cent respectively. In the group of the patients with wound infection complicated by respiratory or urinary tract infection the clinical and bacteriological efficacies equaled 94-100 per cent. The appetite disorder, epigastric pain or nausea were rare. Only in 3 cases the adverse reactions required the treatment discontinuation. Despite the use of ofloxacin for many years, the susceptibility of the main causative agents of surgical infections to the drug remained high: Staphylococcus epidermidis 93.3 per cent, Staph.aureus 94.5 per cent, Pseudomonas aeruginosa 96.5 per cent, Escherichia coll 100 per cent, Proteus spp. 100 per cent, Enterobacter spp. 100 per cent, Acinetobacter spp. 82.3 per cent and Klebsiella spp. 88.8 per cent. The successive use of ofloxacin, at first intravenously for 3-5 days and then orally in the form of tablets for 3-5 days, in the treatment of 15 patients with wound infections of various genesis and localization subjected to osteoplastic reconstructive operations provided positive effects in all the cases and was economically advantageous.
Blatun
L A
LA
Iakovlev
V P
VP
Svetukhin
A M
AM
Puchkova
L S
LS
Izotova
G N
GN
D000284:Administration, Oral; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001437:Bacteriuria / Q000150:complications*; D004334:Drug Administration Schedule; D006801:Humans; D007262:Infusions, Intravenous; D008826:Microbial Sensitivity Tests; D015242:Ofloxacin / Q000009:adverse effects / Q000627:therapeutic use*; D012141:Respiratory Tract Infections / Q000150:complications*; D012189:Retrospective Studies; D013530:Surgical Wound Infection / Q000188:drug therapy*; D016896:Treatment Outcome; D014946:Wound Infection / Q000150:complications / Q000188:drug therapy*
D000890:Anti-Infective Agents; D015242:Ofloxacin